[HTML][HTML] Advances of osteosarcoma models for drug discovery and precision medicine
L Tan, Y Wang, X Hu, G Du, X Tang, L Min - Biomolecules, 2023 - mdpi.com
The management of osteosarcoma (OS) patients presents a significant clinical challenge.
Despite progress in conventional and targeted therapies, the survival rate of OS patients …
Despite progress in conventional and targeted therapies, the survival rate of OS patients …
[HTML][HTML] Strategic electrochemical oxidation of vinblastin sulfate (an anticancer drug) via PVP-functionalized strontium oxide nanoparticles
AR Solangi, N Batool, NH Khand, M Kamboh… - RSC …, 2024 - pubs.rsc.org
Cancer is a primary cause of death worldwide, and considerably impacts mortality rates in
low-and middle-income countries. The rise in chemotherapeutic patients and toxicity of …
low-and middle-income countries. The rise in chemotherapeutic patients and toxicity of …
Does Vinblastine Retain its Anticancer Effect in the Presence of Cyclodextrin? A Preliminary Study
Vinblastine was investigated in the presence of cyclodextrin derivatives on different cancer
cells and it was established that the anticancer activity was unchanged. This was the first …
cells and it was established that the anticancer activity was unchanged. This was the first …
Targeted Biological and Cellular Immunotherapies for Osteosarcoma
GM Robbins - 2023 - search.proquest.com
Osteosarcoma (OSA) is the most common cancer of the bone and third most common cancer
diagnosed in children and adolescent. The five-year survival rate for OSA patients …
diagnosed in children and adolescent. The five-year survival rate for OSA patients …